Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
URGN · against 588 other Healthcare companies listed in US-listed
Ranked #313 of 589 · scores higher than 3% of peers
Bars: peers in each 10-point band of the valuation score277 peers with a valuation score of 0–9, including URGN · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | URGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 577 reported | -5.7% | -4.3% | 47% | 30% | |
| EBITDA yieldHigher is better · 578 reported | -3.7% | -0.8% | 42% | 50% | |
| Free cash flow yieldHigher is better · 553 reported | -9.5% | -2.3% | 30% | 20% | |
| Book yieldHigher is better · 587 reported | -7.9% | 25.9% | 5% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 256M USD | 98 | 80 | |
| 2 | 595M USD | 96 | 97 | |
| 2 | 433M USD | 96 | 81 | |
| 2 | 289M USD | 96 | 57 | |
| 2 | 810M USD | 96 | 69 | |
| 313 | 289M USD | 8 | ||
| 313 | 9.3B USD | 8 | 29 | |
| 313 | 8.5B USD | 8 | 28 | |
| 313 | 1.5B USD | 8 | 39 | |
| 313 | 1.7B USD | 8 | 31 | |
| 313 | 522M USD | 8 | 12 | |
| 313 | 2.2B USD | 8 | 35 | |
| 313 | 1.9B USD | 8 | 42 | |
| 313 | 227M USD | 8 | 24 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score